Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Rhea-AI Summary
Obagi Medical (NASDAQ: WALD) announced a collaboration with DermFx to run the ALOHA Real-World Program for Obagi® saypha® MagIQ™, aiming to translate FDA pivotal trial results into routine med spa practice. The program will use standardized data capture across DermFx’s five Southern California locations and present initial findings internally.
The partnership emphasizes evidence-based rollout, provider training, integrated skincare-injectable protocols, and support for regional practices to evaluate patient outcomes and satisfaction.
Positive
- Launch of an ALOHA real-world evidence program to support Obagi saypha MagIQ adoption
- DermFx participation across five Southern California locations enables multi-site standardized data capture
Negative
- None.
News Market Reaction – WALD
In the Feb 6 session, WALD gained 3.45%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | ALOHA collaboration | Positive | -4.9% | Moxie partnership to run ALOHA real‑world evidence program across practices. |
| Feb 03 | Product launch | Positive | +5.3% | Launch of two‑step Lip Therapy protocol with new resurfacing and SPF products. |
| Jan 30 | ALOHA collaboration | Positive | +13.5% | VIO Med Spa collaboration to collect clinical and patient data for MagIQ. |
| Jan 28 | ALOHA collaboration | Positive | -5.7% | Next Health partnership integrating MagIQ with longevity‑focused wellness clinics. |
| Jan 27 | ALOHA launch partner | Positive | -4.6% | Alpha Aesthetic Partners named ALOHA launch partner for multi‑site evaluation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ALOHA partnership headlines have produced mixed reactions, with some collaborations coinciding with double-digit gains and others with modest single-digit declines, indicating inconsistent trading responses to similar news.
Over late January and early February 2026, WALD issued a series of Obagi Medical announcements centered on product innovation and the ALOHA real‑world evidence program. Multiple collaborations with Alpha Aesthetic Partners, Next Health, VIO Med Spa, and Moxie all focused on structured, multi‑site evaluation of Obagi® saypha® MagIQ™. A separate lip therapy launch also appeared. Price reactions have alternated between gains and pullbacks, underscoring that similar positive news has not produced a consistent trading pattern.
Key Terms
hyaluronic acid medical
real-world data medical
fda pivotal trials regulatory
injectable medical
real-world program medical
hyaluronic acid matrix medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
DermFx selected as a leading regional med spa partner due to its commitment to exceptional patient care, aesthetic innovation, and excellence across Southern California practices
NEW YORK and SUNSET BEACH, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced DermFx as a key partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. DermFx will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple locations and structured evaluation programs that will highlight the value of ALOHA to DermFx.
“This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to introducing this innovative injectable, and as a strong regional leader with deep roots in Southern California, we have the clinical expertise and patient-focused environment to evaluate how trial data performs in real-world med spa settings,” said Erin Alonso, Founder, CEO & Family Nurse Practitioner at DermFx. “Our providers deliver advanced aesthetic treatments daily to thousands of loyal patients across our locations, emphasizing personalized care and outstanding results. That specialized, community-centered experience matters. The ALOHA Program is especially valuable for strong regional practices like ours, not just larger national groups, by providing access to cutting-edge protocols, real-world insights, and integrated skincare-injectable strategies that elevate patient outcomes and help independent med spas compete at the highest level. Obagi’s focus on inclusive, practice-driven evidence aligns perfectly with our dedication to exceptional, transformative patient care.”
The ALOHA Real-World Program is designed to give DermFx providers hands-on experience with Obagi® saypha® MagIQ™ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between patients and their DermFx providers. The program includes a structured evaluation process across DermFx’s multiple locations, with standardized data capture and a demonstration of enhanced value for DermFx practice locations. DermFx will present initial findings at upcoming internal team meetings and regional events, highlighting the benefits of the new protocols and product within the DermFx network.
“Partnering with DermFx is a clear statement of our Aesthetics for All™ ethos and a focus on all practice types delivering exceptional aesthetic outcomes,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA program will serve as a platform for a differentiated launch strategy and underscore Obagi Medical’s commitment to delivering innovative products across every facet of skincare and now injectable aesthetics—empowering strong regional practices like DermFx to thrive alongside larger groups through accessible, high-impact real-world evaluation and protocols.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile1.
For more information about ALOHA, visit https://obagi-professional.com.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,2 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About DermFx
DermFx is a top-ranked medical spa in Orange County and Los Angeles, specializing in advanced aesthetic treatments including injectables, lasers, non-surgical body contouring, and skin rejuvenation. Founded by Erin Alonso, MSN, FNP, with over 25 years of experience in aesthetic medicine, DermFx operates five convenient locations in Southern California and has served tens of thousands of satisfied patients over 20+ years. Known for exceptional patient care, five-star service, and a commitment to confidence-building results, DermFx combines cutting-edge technology with personalized protocols to refresh, restore, and rejuvenate. For more information, visit https://www.dermfx.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
1 Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
2 Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
